1.During the quarter under review, the Income of the Company has grown 15.96% and Profit Before tax has shown an increase of 13.65% as compared to the same period in the previous year.
2.The company is exclusive in the pharmaceutical business segment only.
3.Information on investor's complanits for the quarter, opening-nil, Received-4, Resolved-4 Pending-nil.
4.Previous period figures have been re-grouped / or re-agganged wherever necessary.
5.The above results were taken on record by the Audit Committee and Board of Directors at their respective meeting held on 30th july 2008
|